|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Protein S Activity
MessageMust be collected only at the following locations:
Duke Street Lab Testing
Suburban Pavilion Lab Testing
Women and Babies' Hospital Lab Testing
Duke Street Lab Testing
Suburban Pavilion Lab Testing
Women and Babies' Hospital Lab Testing
Test Code
1779
Alias/See Also
PRSA
LAB0001149
LAB0001149
CPT Codes
85306
Preferred Specimen
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Instructions
Centrifuge light blue-top tube for 15 minutes at approximately 1500 g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet poor plasma into a new plastic vial. Plasma must be free of platelets (<10,000/mcL). Freeze immediately and ship on dry ice.
Transport Container
Plastic vial
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 30 days
Refrigerated: Unacceptable
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis
Methodology
Clot Detection
Setup Schedule
Set up: Tues-Sat; Report available: 1-3 days
Limitations
Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: decrease; Heparin (UFH or LMWH): may falsely increase at values approximately greater than 1.0 IU/mL; Dabigatran or Argatroban (Thrombin Inhibitors): may falsely increase; Rivaroxaban or Apixaban (Factor Xa Inhibitors): may falsely increase.
Reference Range
| Male | 70-150 % normal | ||
| Female | 60-140 % normal | ||
Clinical Significance
Protein S (PS) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PS deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn. In addition, PS deficiency is physiologic in pregnancy.
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K Antagonists (eg. warfarin):
decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Direct Thrombin Inhibitors): may falsely
increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.
Anticoagulant interference: Expected impact by therapeutic levels (potential interference depends upon drug concentration): Vitamin K Antagonists (eg. warfarin):
decrease; Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher levels; Dabigatran or Argatroban (Direct Thrombin Inhibitors): may falsely
increase activity; Rivaroxaban, Apixaban, Edoxaban (Factor Xa Inhibitors): may falsely increase activity.
